Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
OSTO:EXPRS2's 9-Day RSI is ranked better than 75.04% of 1422
companies
in the Biotechnology industry
Industry Median: 50.12
vs OSTO:EXPRS2: 44.00
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
ExpreS2ion Biotech Holding AB 9-Day RSI Related Terms
OSTO:EXPRS2 vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's 9-Day RSI falls into.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a 9-Day RSI of 44.00 as of Jul. 14, 2026. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #355 out of 1422 companies in the Biotechnology industry, placing it in the top 25%.
Is ExpreS2ion Biotech Holding AB's 9-Day RSI too high?
ExpreS2ion Biotech Holding AB's current 9-Day RSI is 44.00. The Biotechnology industry median 9-Day RSI is 50.12. ExpreS2ion Biotech Holding AB's value of 44.00 is 12.2% below this industry median. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #355 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #355 out of 1422 companies for 9-Day RSI. This places ExpreS2ion Biotech Holding AB in the top 25% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 50.12. ExpreS2ion Biotech Holding AB's value of 44.00 is 12.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.12, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ExpreS2ion Biotech Holding AB's current 9-Day RSI of 44.00 is 12.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ExpreS2ion Biotech Holding AB's current 9-Day RSI is 44.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.43, compared to a current price of kr1.46 — trading 57.4% below its estimated fair value. The current 9-Day RSI is 44.00 and 12.2% below the Biotechnology industry median of 50.12. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current 9-Day RSI is 44.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of kr1.46 is trading 57.4% below its estimated GF Value™ of kr3.43.
GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:EXPRS2:
9-Day RSI: 44.00
GF Value™: kr3.43 vs. price of kr1.46 (57.4% below fair value)
Industry Position: 12.2% below the Biotechnology median (#355 of 1422)
No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for OSTO:EXPRS2
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EXPRS2 has been successfully added to your 
